Publication:
Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study

Issued Date

2018-01-11

Resource Type

Letter

ISSN

15280020
00064971

DOI

10.1182/blood-2017-06-790121

Other identifier(s)

2-s2.0-85040441699

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Blood. Vol.131, No.2 (2018), 263-265

Suggested Citation

Ali T. Taher, Zeynep Karakas, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Aurelio Maggio, Stefano Rivella, Norbert Hollaender, Bruyere Mahuzier, Brian Gadbaw, Yesim Aydinok Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study. Blood. Vol.131, No.2 (2018), 263-265. doi:10.1182/blood-2017-06-790121 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/45268

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study

Author(s)

Ali T. Taher
 Zeynep Karakas
 Elena Cassinerio
 Noppadol Siritanaratkul
 Antonis Kattamis
 Aurelio Maggio
 Stefano Rivella
 Norbert Hollaender
 Bruyere Mahuzier
 Brian Gadbaw
 Yesim Aydinok

Other Contributor(s)

American University of Beirut Medical Center
 Università degli Studi di Milano
 The Children's Hospital of Philadelphia
 National and Kapodistrian University of Athens
 Novartis Pharma S.A.S.
 Istanbul Üniversitesi Tıp Fakültesi
 Faculty of Medicine, Siriraj Hospital, Mahidol University
 Novartis International AG
 Ege University Medical School
 Novartis Pharmaceuticals Corporation
 UOSD MICI-A.O. Ospedali Riuniti “Villa Sofia-Cervello” Palermo

Keyword(s)

Biochemistry, Genetics and Molecular Biology
 Immunology and Microbiology
 Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/45268

Collections

Scopus 2018